Juerg Zimmermann
Impact in
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments
- Organic Chemistry top 5%
- Synthesis and biological activity
- Quinazolinone synthesis and applications
Papers in
-
- Chronic Myeloid Leukemia Treatments 2
- Co-authors
- Elisabeth BuchdungerRenaud CapdevilleAlex MatterPeter TraxlerPaul W. ManleyTerence O’ReillyPascal FuretJeanette M. Wood
- Journals
- Tetrahedron Letters (3 papers)Journal of the American Chemical Society (2 papers)Biogerontology (1 paper)Nature Reviews Drug Discovery (1 paper)Journal of Computer-Aided Molecular Design (1 paper)
- Partner nations
- SwitzerlandUnited StatesAustria
In The Last Decade
Juerg Zimmermann
10 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Hematology 309
- Organic Chemistry 581
- Genetics 170
- Oncology 356
- Molecular Biology 716
Countries citing papers authored by Juerg Zimmermann
This map shows the geographic impact of Juerg Zimmermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juerg Zimmermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juerg Zimmermann more than expected).
Fields of papers citing papers by Juerg Zimmermann
This network shows the impact of papers produced by Juerg Zimmermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juerg Zimmermann. The network helps show where Juerg Zimmermann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Juerg Zimmermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2010 | 3 | |
| 3 | 2009 | 5 | |
| 4 | 2005 | 30 | |
| 5 | 2003 | 32 | |
| 6 | Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Hit paper breakdown → | 2002 | 1067 |
| 7 | 2001 | 265 | |
| 8 | 2000 | 32 | |
| 9 | 1988 | 90 | |
| 10 | 1985 | 52 |
About Juerg Zimmermann
Juerg Zimmermann is a scholar working on Gastroenterology, Hematology, Oncology, Organic Chemistry and Aquatic Science, having authored 10 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (2 papers), HER2/EGFR in Cancer Research (2 papers), Cancer-related Molecular Pathways (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Cancer therapeutics and mechanisms (1 paper), Advanced Breast Cancer Therapies (1 paper), Asymmetric Synthesis and Catalysis (1 paper) and DNA and Nucleic Acid Chemistry (1 paper). The work is most often cited by research in Hematology (309 citations), Organic Chemistry (581 citations), Genetics (170 citations), Oncology (356 citations) and Molecular Biology (716 citations). Juerg Zimmermann has collaborated with scholars based in Switzerland, United States and Austria. Frequent co-authors include Elisabeth Buchdunger, Renaud Capdeville, Alex Matter, Peter Traxler, Paul W. Manley, Terence O’Reilly, Pascal Furet, Jeanette M. Wood, Guido Bold and Giorgio Caravatti. Their work appears in journals such as Tetrahedron Letters, Journal of the American Chemical Society, Biogerontology, Nature Reviews Drug Discovery and Journal of Computer-Aided Molecular Design.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.